https://www.selleckchem.com/pr....oducts/ldn193189.htm
Our results demonstrated the in vivo efficacy of the novel tubulin inhibitor plocabulin in PDX models of GIST and challenge the established view that GIST are resistant to cytotoxic agents in general and to tubulin inhibitors in particular. Our findings provide a convincing rationale for early clinical exploration of plocabulin in GIST and warrant further exploration of this class of drugs in the management of this common sarcoma subtype.Conventional electric stimuli of micro- and millisecond duration excite or activate cells at volta
Curtir
Comentario
Compartilhar
